Abstract
Compared with the annual record high, 17 therapeutic monoclonal antibodies (mAb) approved in 2017, this year total 16 therapeutic mAb were approved by FDA, interestingly 4 of them targeted at VEGF (Vascular Endothelial Growth Factor), two indicated for solid tumor, two for Neovascular (Wet) Age-Related Macular Degeneration [1]. Monoclonal antibody technique was created by Georges Köhler, César Milstein, and Niels Kaj Jerne in 1975 by using a mouse x mouse hybridoma. In 1984 they were awarded the Nobel Prize in Medicine for the discovery. Eight years later, in 1992 US FDA approved the first therapeutic mAb muromonab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
